Related Experiment Video
Updated: Nov 25, 2025
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort
Ye-Xuan Cao1,2, Hui-Wen Zhang1, Jing-Lu Jin1
1State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Insights
High lipoprotein(a) [Lp(a)] levels predict worse long-term outcomes in myocardial infarction (MI) survivors. Measuring Lp(a) can improve risk stratification and guide future management for these high-risk individuals.
Area of Science:
- Cardiology
- Atherosclerosis Research
- Clinical Outcomes
Background:
- Lipoprotein(a) [Lp(a)] is linked to atherothrombotic diseases.
- The prognostic value of Lp(a) in long-term outcomes post-myocardial infarction (MI) is not fully understood.
Purpose of the Study:
- To investigate the association between Lp(a) levels and long-term cardiovascular events (CVEs) and cardiac mortality in patients with previous MI.
- To evaluate the utility of Lp(a) in improving risk prediction models for post-MI patients.
Main Methods:
- Prospective cohort study of 3,864 post-MI patients.
- Lp(a) levels measured by immunoturbidimetry, categorized by quartiles.
- Cox proportional hazards models used to assess outcomes over a median 4.1-year follow-up.
Main Results:
- Elevated Lp(a) levels were significantly higher in patients who experienced CVEs (p=0.001).
- Higher Lp(a) was associated with increased cumulative rates of CVEs and cardiac mortality (log-rank p<0.001).
- Multivariate analysis showed Lp(a) as an independent predictor of CVEs (aHR:1.22) and cardiac mortality (aHR:1.30).
Conclusions:
- Elevated Lp(a) levels are associated with worse long-term clinical outcomes in patients with prior MI.
- Lp(a) measurement can enhance risk stratification and inform management strategies for high-risk post-MI individuals.
- Lp(a) significantly improves prognostic models, indicating its clinical relevance.
Abstract:
Lipoprotein(a) [Lp(a)] has been documented to be associated with atherothrombotic diseases. However, the prognostic impact of Lp(a) on long-term clinical outcomes among patients with previous myocardial infarction (MI) remains unclear. In this prospective cohort study, we consecutively enrolled 3,864 post-MI patients to assess the cardiovascular events (CVEs), including MI, ischemic stroke, and cardiac mortality. Lp(a) levels were determined using an immunoturbidimetry assay and the participants were categorized according to Lp(a) quartiles. The Cox proportional hazards model was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). During a median follow-up of 4.1 years, 331 (8.6%) CVEs were identified. Lp(a) was significantly higher in patients with CVEs (25.17 [11.13-47.83] vs. 18.18 [7.90-40.30] mg/dL, p = 0.001). The cumulative rates of CVEs and cardiac mortality were significantly higher in patients with high Lp(a) levels (both log-rank p < 0.001). Multivariate Cox regression analysis showed a significant correlation between Lp (a) levels treated as a natural logarithm-transformed continuous variable and increased CVEs (adjusted HR:1.22, 95% CI:1.09-1.35, p = 0.001) or cardiac mortality (HR:1.30, 95% CI:1.14-1.48, p < 0.001). The addition of Lp(a) to a prognostic model revealed a significant improvement in C-statistic, net reclassification, and integrated discrimination. In conclusion, elevated levels of Lp(a) were indeed associated with long-term worse outcomes in patients with prior MI, suggesting a novel hint that the measurement of Lp(a) might help in risk stratification and future management in those high-risk individuals.
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
01:30Acute Coronary Syndrome III: Diagnostic Studies